mRNA |
Cerulenin |
CTRPv2 |
pan-cancer |
AAC |
0.085 |
0.02 |
mRNA |
tigecycline |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
0.02 |
mRNA |
Doxorubicin |
FIMM |
pan-cancer |
AAC |
-0.33 |
0.02 |
mRNA |
tivozanib |
GDSC1000 |
pan-cancer |
AAC |
-0.085 |
0.02 |
mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.09 |
0.02 |
mRNA |
Cetuximab |
GDSC1000 |
pan-cancer |
AAC |
0.081 |
0.02 |
mRNA |
CAY10603 |
GDSC1000 |
pan-cancer |
AAC |
-0.074 |
0.02 |
mRNA |
piperlongumine:MST-312 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.087 |
0.03 |
mRNA |
crizotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.085 |
0.03 |
mRNA |
SGC0946 |
GDSC1000 |
pan-cancer |
AAC |
-0.085 |
0.03 |